开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大关注。 湘财证券研报表示，站在当前时点来看，医药行业受医保控费影响的预期已充分反映，多层次的支付体 系正在建立，医疗需求的刚性将共同推动行业企稳回升，建议关注高成长及预期改善两大方向。 低位埋伏港股医药机遇，借道ETF效率更高，高弹性，T+0。港股通创新药ETF（520880）及其场外联 接基金（025221），100%布局创新药研发类公司，前十大权重股占比超73%，龙头属性突出。港股通 医疗ETF华宝（159137），锚定医疗创新，囊括脑机接口、AI医疗、互联网药店等热点概念，同时覆盖 创新药全产业链龙头。 2月份以来，港股医药、医疗以一波强势连阳行情，持续修复失地。热门ETF方面，2月10日，港股通创 新药ETF（520880）、港股通医疗ETF（159137）早盘悉数涨逾2%，其中，港股通创新药ETF （520880）涨幅更是逼近3%。值得一提的是，自2月份以来的7个交易日，上述2只ETF双双 ...

Investment Rating - The report maintains an "Overweight" rating for the medical device industry [2][6]. Core Insights - The medical device procurement scale is experiencing a partial decline due to high base effects, but there are opportunities in the surgical robot market [2]. - The report emphasizes that the ongoing implementation of equipment upgrade policies is expected to drive long-term procurement levels in the medical device sector, recommending companies that are likely to benefit from these policies [4]. - The report highlights that the four ministries jointly issued a notice in 2024 aiming for a more than 25% increase in medical equipment investment by 2027 compared to 2023, which is expected to enhance the configuration of high-end equipment to levels comparable to middle-income countries [6]. Summary by Sections Investment Recommendations - The report suggests maintaining an "Overweight" rating and recommends companies likely to benefit from the equipment upgrade policies, including Mindray Medical, United Imaging, Kaili Medical, Aohua Endoscopy, and Jingfeng Medical-B. It also suggests paying attention to MicroPort Scientific-B [6]. Monthly Procurement Data - In January 2026, the procurement scale for new devices showed a year-on-year decline: MR down 22.6%, CT down 25.6%, DR down 18.2%, ultrasound down 10.1%, while endoscopy grew by 1.1%, and surgical robots declined by 20.1%. Company-specific performance showed United Imaging MR down 36.5%, United Imaging CT up 8.5%, Mindray ultrasound up 10.9%, Kaili ultrasound down 14.8%, Kaili endoscopy up 55.4%, and Aohua endoscopy down 11.7% [6]. Policy Impact - The report discusses the release of a guideline by the National Healthcare Security Administration on January 20, 2026, which establishes a unified pricing project for surgical robots, expected to accelerate the penetration and application of robotic surgery technology [6].

Summary of Industry Reports Industry: Pharmaceutical and Biotechnology Key Points from Document 1 1. **Raw Material Supply Changes**: The supply of raw materials is accelerating, with a focus on subsequent volume and price changes [1] 2. **Global GLP-1 Landscape**: The global GLP-1 landscape is continuously evolving, and Chinese companies are still pursuing international expansion [1] 3. **Small Nucleic Acid Sector**: Leading companies are gradually entering the small nucleic acid field, with market progress expected to drive the development of supporting industrial chains [1] 4. **Retail Pharmaceutical Market Outlook**: The retail pharmaceutical market is expected to improve by Q4 2025, with an enhanced positioning of chain pharmacies [1] 5. **Value of Oral Immunomodulatory Drugs**: Emphasis on the market value of oral immunomodulatory drugs [1] 6. **Investment Recommendations**: Recommended companies include Chuaning Biological, with attention to Lianbang Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, as well as synthetic biology companies [1] 7. **CXO Order Trends**: Positive trends in CXO orders and rising prices for safety evaluation orders, with recommendations for Yinos and Zhaoyan New Drug, and recommendations for Weiya Biological and Puris [1] Key Points from Document 2 1. **Small Nucleic Acids Breakthrough**: Continuous breakthroughs in small nucleic acids, with ongoing progress in external authorizations by Chinese companies, recommending Yuekang Pharmaceutical and Sunshine Novo [2] 2. **Self-Immunity Field**: Focus on breakthroughs in oral directions and difficult-to-treat areas like UC/IBD, recommending Yahong Pharmaceutical and Yifang Biological [2] 3. **GLP-1 Weight Loss Authorizations**: Recommendations for Zhongsheng Pharmaceutical in the GLP-1 weight loss field, with attention to Lianbang Pharmaceutical and Shiyao Group [2] 4. **ZAP-X Radiation Therapy Equipment**: Initiation of domestic clinical research for ZAP-X radiation therapy equipment, recommending Baiyang Pharmaceutical [2] 5. **Policy Support for Brain-Computer Interface Technology**: Support for the development of invasive brain-computer interfaces, recommending Meihao Medical and Botuo Biological, with accelerated approvals for non-invasive devices, focusing on Xiangyu Medical and Kefu Medical [2] 6. **High-Value Medical Device Exports**: Breakthroughs in exports of high-value medical consumables, with attention to Chunli Medical, Aikang Medical, Nanwei Medical, and Baixin An [2] 7. **AI in Healthcare**: Accelerated applications of AI in healthcare, reshaping application scenarios and bringing changes in industrial chain value, recommending Anbiping and focusing on Yuyue Medical and Meinian Health [2] 8. **Chain Pharmacy Industry**: Industry consolidation in chain pharmacies, with policy support for enhanced positioning, recommending Yifeng Pharmacy and Laobaiqing, with attention to Yixintang [2]

Core Viewpoint - The rise of AI medical consultation in China is transforming healthcare access and efficiency, but concerns about reliability and data protection persist [4][11][14]. Group 1: AI Medical Consultation Overview - By the end of 2025, AI medical consultation advertisements are expected to be ubiquitous in Beijing, indicating a significant market presence [1]. - Users like Liu Yu are turning to AI for quick medical advice, completing processes that traditionally take hours in just minutes [3][4]. - Major companies such as JD Health, Ant Group, and Baidu are launching AI medical products, reflecting a competitive landscape in the sector [4]. Group 2: Functionality and Training of AI - AI medical products are categorized into two main types: those for general patients and those for healthcare professionals [7][10]. - The training of AI involves extensive input of medical knowledge and real patient interaction data to enhance diagnostic accuracy [7][12]. - Current AI models have shown a top-5 diagnostic accuracy rate of 97%, with the first suggestion accuracy at approximately 80% [12]. Group 3: Advantages and Limitations - AI consultation offers convenience, operating 24/7 without the need for appointments, which alleviates pressure on overburdened hospitals [10][11]. - AI is best suited for managing minor symptoms and chronic conditions, while complex cases still require in-person consultations [11][14]. - The technology's limitations include potential inaccuracies and the inability to replace physical examinations, which are crucial for accurate diagnosis [11][12]. Group 4: Legal and Ethical Considerations - The question of liability in cases of AI misdiagnosis remains unresolved, with current regulations not clearly defining responsibility [13][14]. - Experts suggest that AI should be viewed as a supportive tool rather than a replacement for human doctors, emphasizing the need for transparency in AI recommendations [12][14]. - The development of a regulatory framework is necessary to ensure the safe and effective use of AI in healthcare, with suggestions for a tiered system similar to that used in autonomous driving [16].

Group 1: Pharmaceutical Industry - The pharmaceutical index increased by 0.14%, outperforming the CSI 300 index by 1.47% during the week [2][6] - The report highlights the potential of molecular glue technology to target "undruggable" proteins, expanding the scope for innovative drug development [8][9] - Recommended stocks in the innovative drug sector include Heng Rui Medicine, China Biologic Products, and Yuan Dong Biology, among others [11][9] Group 2: Construction and Building Materials - Major engineering projects are identified as a key focus for the "14th Five-Year Plan," with significant investments planned across various provinces [13][14] - The report notes that infrastructure projects will dominate investment, with substantial funding allocated to transportation, municipal, and energy sectors [14] - The issuance of special bonds has increased significantly, with a total of 5,164.55 billion yuan issued as of February 8, 2026, marking a year-on-year increase of 125.35% [15] Group 3: Real Estate - The Shanghai government has initiated the acquisition of second-hand homes for rental housing projects, indicating a strategic move to stabilize the real estate market [19][21] - New home sales in 42 key cities totaled 1.48 million square meters, a slight decrease of 0.1% week-on-week, while second-hand home sales fell by 3.0% [20][19] - The report suggests that the real estate market is entering a phase of structural differentiation, with high-quality housing expected to see increased demand [23] Group 4: Overseas and Education Research - The first round of negotiations between the US and Iran concluded, with market sentiment shifting towards risk assets, particularly in AI and commercial aerospace sectors [26][30] - Bloom Energy reported better-than-expected earnings, with Q4 2025 revenue reaching $777.8 million, a year-on-year increase of 35.9% [26] - The quantum computing sector is gaining attention, with NERSC announcing a call for proposals utilizing neutral atom quantum processors [28]

Market Overview - The A-share pharmaceutical and biotechnology index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points and the ChiNext index by 2.06 percentage points, ranking 15th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index fell by 1.41%, outperforming the Hang Seng Index by 1.65 percentage points [4] R&D Progress - Heng Rui Medicine submitted an NDA for HRS-9531; He Yu Bio's ABSK043 clinical application is under new undertaking [5] - Xianwei's Enogrelide is in Phase III clinical trials; Xiansheng Pharmaceutical's SIM0278 is in Phase II clinical trials; Yingxi Intelligent's ISM-4808 is in Phase I clinical trials [5] Investment Outlook - Continuous attention to AI healthcare-related investment opportunities is advised [6] - The Ministry of Industry and Information Technology, along with eight other ministries, issued the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [6] - The plan focuses on enhancing the stable supply of key traditional Chinese medicine raw materials, improving digital and green levels, and optimizing the structure of the traditional Chinese medicine industry, which is expected to benefit the sector through policy dividends [6] Investment Strategy for 2026 - Future investments in the pharmaceutical sector should increasingly focus on the intrinsic clinical value of medicines, addressing clinical needs of patients [7] - Both domestic medical insurance policies and global expansion strategies are placing higher premiums on clinical value [7]

Core Viewpoint - The company, Yidu Tech (02158), is actively repurchasing shares, signaling confidence in its value and positively impacting market sentiment [1] Group 1: Share Buyback Activity - On February 9, Yidu Tech announced a share buyback, repurchasing 910,000 shares at approximately HKD 5.77 per share, totaling over HKD 5 million [1] - This marks the company's eleventh consecutive trading day of intensive buybacks, with a cumulative repurchase amount of approximately HKD 58 million [1] - The stock price of Yidu Tech rose by 3.39% on the same day, closing at HKD 5.79, reflecting a positive market response to the buyback [1] Group 2: Analyst Ratings and Market Position - Citigroup maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11 [1] - The company has established a strong presence in national-level AI medical application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions [1] - Yidu Tech's products, such as the Doctor Copilot, and its consumer-facing offering "Yidu Qianyu" demonstrate solid technical capabilities, performing well in accuracy and traceability of medical evidence in tests conducted by Citigroup [1] - The company is positioned in the first tier alongside leading products like Ant Group's "Alfu" and iFlytek's "Xiao Yi," creating a synergistic layout between its To-G (government and hospital) and To-C (consumer) business segments [1]

Core Viewpoint - The company, Yidu Tech (02158), has been actively repurchasing its shares, signaling confidence in its value and positively impacting market sentiment [1] Group 1: Share Buyback Activity - On February 9, Yidu Tech announced a share buyback of 910,000 shares at approximately HKD 5.77 per share, totaling over HKD 5 million [1] - This marks the 11th consecutive trading day of intensive buybacks, with a cumulative repurchase amount of approximately HKD 58 million [1] - The stock price of Yidu Tech rose by 3.39% on the same day, closing at HKD 5.79, reflecting a positive market response to the buyback [1] Group 2: Analyst Ratings and Market Position - Citigroup maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11 [1] - The company has established a strong presence in national-level AI medical application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions [1] - Yidu Tech's products, such as the Doctor Copilot, and its consumer-facing "Yidu Qianyu" demonstrate solid technical capabilities, ranking alongside leading products in accuracy and traceability of medical evidence [1]

来源：新浪基金 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大关注。* 再来看港股通医疗板块表现，AI医疗、脑机接口概念股较为活跃，大权重领衔涨势，京东健康、阿里 健康、平安好医生齐涨3%左右，港股通医疗ETF华宝（159137）日线五连阳。 目前AI医疗在C端的渗透正在加速，从智能问诊到慢病管理的应用场景不断拓展，推动阿里健康、京东 健康等港股互联网医疗平台价值重估。 中信建投证券指出，港股器械整体创新属性较强，部分企业的创新产品具有license-out或被并购的可 能。基本面维度，行业内部多数公司经营业绩持续改善，低估值投资价值凸显。事件方面，预计迈瑞医 疗、可孚医疗今年将在港股上市，港股医疗器械板块效应和投资机会或将增多。* 2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振， 百济神州涨超3%，石药集团、中国生物制药、三生制药集 ...

2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振， 百济神州涨超3%，石药集团、中国生物制药、三生制药集体跟涨。 100%创新药研发标的——港股通创新药ETF（520880）高开后上探2.75%，收涨1.77%成功连阳，一并 站上10日均线，全天成交3.81亿元。 2月8日晚，信达生物公告，公司与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研 发进程。信达将获3.5亿美元首付款，最高可获85亿美元里程碑付款及大中华区以外净销售额梯度分 成。 2025年中国创新药License-out总交易规模达到创纪录的1357亿美元，2026年开年以来重磅合作频出，除 信达外，1月份石药-阿斯利康（185亿美元）、荣昌-艾伯维（56亿美元）两笔超级BD均充分验证国产 创新药管线的全球价值。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大 ...